A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
NCT01327053
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
230
Enrollment
INDUSTRY
Sponsor class
Conditions
Basal Cell Carcinoma
Interventions
DRUG:
LDE225
Sponsor
Novartis Pharmaceuticals